Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study
•Immunity from natural SARS-CoV-2 infection is protective in healthcare workers•Secondary infection is associated with low or absent serum neutralizing titer•Anti-Spike IgG were not significantly lower in subjects with secondary infections•Secondary infection is usually asymptomatic or mildly sympto...
Saved in:
Published in | International journal of infectious diseases Vol. 109; pp. 199 - 202 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Ltd
01.08.2021
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | •Immunity from natural SARS-CoV-2 infection is protective in healthcare workers•Secondary infection is associated with low or absent serum neutralizing titer•Anti-Spike IgG were not significantly lower in subjects with secondary infections•Secondary infection is usually asymptomatic or mildly symptomatic•Vaccination of SARS-CoV-2-seronegative subjects might be prioritized
The protection from SARS-CoV-2 infection induced by SARS-CoV-2 anti-S1 and anti-S2 IgG antibody positivity resulting from natural infection was evaluated.
The frequency of SARS-CoV-2 infection (as determined by virus RNA detection) was evaluated in a group of 1,460 seropositive and a control group of 8,150 seronegative healthcare workers in three Centres of Northern Italy in the period June-November 2020. Neutralizing serum titers were analyzed in seropositive subjects with or without secondary SARS-CoV-2 infection.
During the 6-month survey, 1.78% seropositive subjects developed secondary SARS-CoV-2 infection while 6.63% seronegative controls developed primary infection (odds ratio: 0.26; 95% confidence interval: 0.17-0.38). Secondary infection was associated with low or absent serum neutralizing titer (p<0.01) and was mildly symptomatic in 45.8% cases vs 71.4% symptomatic primary infections (odds ratio: 0.34; 95% confidence interval: 0.16-0.78).
Immunity from natural infection appears protective from secondary infection; therefore, vaccination of seronegative subjects might be prioritized. |
---|---|
AbstractList | Objective: The protection from SARS-CoV-2 infection induced by SARS-CoV-2 anti-S1 and anti-S2 IgG antibody positivity resulting from natural infection was evaluated. Methods: The frequency of SARS-CoV-2 infection (as determined by virus RNA detection) was evaluated in a group of 1,460 seropositive and a control group of 8,150 seronegative healthcare workers in three Centres of Northern Italy in the period June-November 2020. Neutralizing serum titers were analyzed in seropositive subjects with or without secondary SARS-CoV-2 infection. Results: During the 6-month survey, 1.78% seropositive subjects developed secondary SARS-CoV-2 infection while 6.63% seronegative controls developed primary infection (odds ratio: 0.26; 95% confidence interval: 0.17-0.38). Secondary infection was associated with low or absent serum neutralizing titer (p<0.01) and was mildly symptomatic in 45.8% cases vs 71.4% symptomatic primary infections (odds ratio: 0.34; 95% confidence interval: 0.16-0.78). Conclusions: Immunity from natural infection appears protective from secondary infection; therefore, vaccination of seronegative subjects might be prioritized. OBJECTIVEThe protection from SARS-CoV-2 infection induced by SARS-CoV-2 anti-S1 and anti-S2 IgG antibody positivity resulting from natural infection was evaluated. METHODSThe frequency of SARS-CoV-2 infection (as determined by virus RNA detection) was evaluated in a group of 1,460 seropositive and a control group of 8,150 seronegative healthcare workers in three Centres of Northern Italy in the period June-November 2020. Neutralizing serum titers were analyzed in seropositive subjects with or without secondary SARS-CoV-2 infection. RESULTSDuring the 6-month survey, 1.78% seropositive subjects developed secondary SARS-CoV-2 infection while 6.63% seronegative controls developed primary infection (odds ratio: 0.26; 95% confidence interval: 0.17-0.38). Secondary infection was associated with low or absent serum neutralizing titer (p<0.01) and was mildly symptomatic in 45.8% cases vs 71.4% symptomatic primary infections (odds ratio: 0.34; 95% confidence interval: 0.16-0.78). CONCLUSIONSImmunity from natural infection appears protective from secondary infection; therefore, vaccination of seronegative subjects might be prioritized. • Immunity from natural SARS-CoV-2 infection is protective in healthcare workers • Secondary infection is associated with low or absent serum neutralizing titer • Anti-Spike IgG were not significantly lower in subjects with secondary infections • Secondary infection is usually asymptomatic or mildly symptomatic • Vaccination of SARS-CoV-2-seronegative subjects might be prioritized •Immunity from natural SARS-CoV-2 infection is protective in healthcare workers•Secondary infection is associated with low or absent serum neutralizing titer•Anti-Spike IgG were not significantly lower in subjects with secondary infections•Secondary infection is usually asymptomatic or mildly symptomatic•Vaccination of SARS-CoV-2-seronegative subjects might be prioritized The protection from SARS-CoV-2 infection induced by SARS-CoV-2 anti-S1 and anti-S2 IgG antibody positivity resulting from natural infection was evaluated. The frequency of SARS-CoV-2 infection (as determined by virus RNA detection) was evaluated in a group of 1,460 seropositive and a control group of 8,150 seronegative healthcare workers in three Centres of Northern Italy in the period June-November 2020. Neutralizing serum titers were analyzed in seropositive subjects with or without secondary SARS-CoV-2 infection. During the 6-month survey, 1.78% seropositive subjects developed secondary SARS-CoV-2 infection while 6.63% seronegative controls developed primary infection (odds ratio: 0.26; 95% confidence interval: 0.17-0.38). Secondary infection was associated with low or absent serum neutralizing titer (p<0.01) and was mildly symptomatic in 45.8% cases vs 71.4% symptomatic primary infections (odds ratio: 0.34; 95% confidence interval: 0.16-0.78). Immunity from natural infection appears protective from secondary infection; therefore, vaccination of seronegative subjects might be prioritized. |
Author | Klersy, Catherine Baldanti, Fausto Percivalle, Elena Marena, Carlo Luzzaro, Francesco Lo Cascio, Giuliana Cassaniti, Irene Cutti, Sara Paolucci, Stefania Novelli, Viola De Vito, Giovanni Lilleri, Daniele Schiavo, Roberta Sarasini, Antonella Rovida, Francesca |
Author_xml | – sequence: 1 givenname: Francesca surname: Rovida fullname: Rovida, Francesca organization: Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy – sequence: 2 givenname: Irene surname: Cassaniti fullname: Cassaniti, Irene organization: Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy – sequence: 3 givenname: Elena surname: Percivalle fullname: Percivalle, Elena organization: Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy – sequence: 4 givenname: Antonella surname: Sarasini fullname: Sarasini, Antonella organization: Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy – sequence: 5 givenname: Stefania surname: Paolucci fullname: Paolucci, Stefania organization: Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy – sequence: 6 givenname: Catherine surname: Klersy fullname: Klersy, Catherine organization: Biometry and Clinical Epidemiology Service, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy – sequence: 7 givenname: Sara surname: Cutti fullname: Cutti, Sara organization: Medical Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy – sequence: 8 givenname: Viola surname: Novelli fullname: Novelli, Viola organization: Medical Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy – sequence: 9 givenname: Carlo surname: Marena fullname: Marena, Carlo organization: Medical Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy – sequence: 10 givenname: Francesco surname: Luzzaro fullname: Luzzaro, Francesco organization: Clinical Microbiology and Virology Unit, Lecco A. Manzoni Hospital, Lecco, Italy – sequence: 11 givenname: Giovanni surname: De Vito fullname: De Vito, Giovanni organization: Occupational Medicine Unit, A. Manzoni Hospital, Lecco, School of Medicine & Surgery, Milano Bicocca University – sequence: 12 givenname: Roberta surname: Schiavo fullname: Schiavo, Roberta organization: Microbiology Unit, Clinical Pathology Department, Guglielmo da Saliceto Hospital, Piacenza, Italy – sequence: 13 givenname: Giuliana surname: Lo Cascio fullname: Lo Cascio, Giuliana organization: Microbiology Unit, Clinical Pathology Department, Guglielmo da Saliceto Hospital, Piacenza, Italy – sequence: 14 givenname: Daniele surname: Lilleri fullname: Lilleri, Daniele email: d.lilleri@smatteo.pv.it organization: Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy – sequence: 15 givenname: Fausto surname: Baldanti fullname: Baldanti, Fausto organization: Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy |
BookMark | eNp9Uk2P0zAQjdAi9gP-ACcfuaT4OwlCSKtqgUorkNgVV8uxJ1uX1C62U9Q_yO_C2VagvXDyaGbeezPjd1md-eChql4TvCCYyLebhds4u6CYkgVuFhizZ9UFaZu2ZoKQsxJTTOquIfS8ukxpgzHmUrYvqnPGKaeNZBfV75U3zoI3gMKA7q6_3dXL8L2myPkBTHbBlwitQY95jYyOgH6F-ANiQkMMW_QlxLyG6NEq6_GAep3AooLRPrs-2ANKWecpvUNuu508oF0M-UT7iE9ggrc6Hv7p1egaRcgxpN2c2JfB-gRxr-eiHssQCeqCKh3jWNRSnuzhZfV80GOCV6f3qrr_eHO__Fzffv20Wl7f1oZ3ba7bRutGdLSnfJB9bzHuQJvBWCObVoieN0MPXBBJLQjZGUxa6AhrW2GE1IZdVasjrQ16o3bRbcvoKminHhMhPigdszMjqA73EhjBgpKWd4x3wPqOYM46JgbMh8L14ci1m_otWANlIz0-IX1a8W6tHsJetVRiIVgheHMiiOHnBCmrrUsGxlF7CFNSVAhMJSGcllZ6bDXlrCnC8FeGYDV7SW3U7CU1e0nhRhUvFdD7IwjKQfcOokrGzU6xLpafKSu7_8H_ADaz14g |
CitedBy_id | crossref_primary_10_3390_v13112261 crossref_primary_10_1371_journal_pone_0297901 crossref_primary_10_3390_microorganisms10061250 crossref_primary_10_2139_ssrn_3944582 crossref_primary_10_1186_s12916_022_02286_4 crossref_primary_10_3390_ijerph20021182 crossref_primary_10_1016_j_ijid_2022_06_028 crossref_primary_10_3390_healthcare10050896 crossref_primary_10_3390_ijms24108746 crossref_primary_10_1038_s41375_022_01578_1 crossref_primary_10_3390_ijerph19042282 crossref_primary_10_1038_s41467_021_26154_6 crossref_primary_10_12968_ijtr_2021_0201 crossref_primary_10_3389_fimmu_2021_786554 crossref_primary_10_2139_ssrn_3987537 crossref_primary_10_1001_jamanetworkopen_2022_1313 crossref_primary_10_3934_mbe_2022216 |
Cites_doi | 10.1016/j.immuni.2020.04.023 10.1016/S0140-6736(21)00675-9 10.1056/NEJMoa2035389 10.1056/NEJMoa2034545 10.2807/1560-7917.ES.2020.25.24.2001031 10.1080/22221751.2021.1872352 10.1016/j.cell.2020.05.015 10.1093/infdis/jiaa659 10.1016/S1473-3099(20)30764-7 10.1016/S0140-6736(20)32661-1 |
ContentType | Journal Article |
Copyright | 2021 The Author(s) 2021 The Author(s) 2021 |
Copyright_xml | – notice: 2021 The Author(s) – notice: 2021 The Author(s) 2021 |
DBID | 6I. AAFTH AAYXX CITATION 7X8 5PM DOA |
DOI | 10.1016/j.ijid.2021.07.003 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Public Health |
EISSN | 1878-3511 |
EndPage | 202 |
ExternalDocumentID | oai_doaj_org_article_90b6e310521849349e3b91043935f04f 10_1016_j_ijid_2021_07_003 S1201971221005580 |
GroupedDBID | --- --K .1- .FO .~1 0R~ 0SF 1B1 1P~ 1~. 1~5 29J 3O- 3V. 4.4 457 4G. 53G 5GY 5VS 6I. 7-5 71M 7X7 88E 8C1 8FI 8FJ 8FQ 8R4 8R5 AACTN AAEDW AAFTH AAIKJ AALRI AAQFI AAQXK AARKO AAXUO ABBQC ABFRF ABMAC ABUWG ABVKL ACGFO ADBBV ADEZE ADMUD AEFWE AEKER AENEX AEVXI AEXQZ AFCTW AFKRA AFRHN AFTJW AGEKW AGHFR AGYEJ AHMBA AITUG AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ ASPBG AVWKF AZFZN BAWUL BCNDV BENPR BPHCQ BR6 BVXVI CCPQU CS3 DIK DU5 DWQXO E3Z EBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FNPLU FYUFA G-Q GBLVA GROUPED_DOAJ GX1 HMCUK HVGLF HZ~ IHE IXB J1W KQ8 M1P M3C M3G M41 MO0 N9A NCXOZ O-L O9- OD- OK1 OO. OZT P-8 P-9 P2P PC. PQQKQ PROAC PSQYO Q2X Q38 QTD R2- RIG ROL RPZ RWL RXW SDF SDG SEL SES SEW SSZ TAE UKHRP UNMZH Z5R AAYXX ADVLN AFJKZ AKRWK ALIPV CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c498t-87aa7592b24f6bbd009eacfcdc67855b47fbe45162de569c018e913885c56ac3 |
IEDL.DBID | ABVKL |
ISSN | 1201-9712 |
IngestDate | Tue Oct 22 15:07:00 EDT 2024 Tue Sep 17 21:17:21 EDT 2024 Fri Oct 25 10:40:21 EDT 2024 Thu Sep 26 15:23:48 EDT 2024 Fri Feb 23 02:37:08 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | SARS-CoV-2 infection neutralizing antibody immune protection secondary infection |
Language | English |
License | This is an open access article under the CC BY-NC-ND license. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c498t-87aa7592b24f6bbd009eacfcdc67855b47fbe45162de569c018e913885c56ac3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 Equally contributed |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S1201971221005580 |
PMID | 34242763 |
PQID | 2550261142 |
PQPubID | 23479 |
PageCount | 4 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_90b6e310521849349e3b91043935f04f pubmedcentral_primary_oai_pubmedcentral_nih_gov_8260553 proquest_miscellaneous_2550261142 crossref_primary_10_1016_j_ijid_2021_07_003 elsevier_sciencedirect_doi_10_1016_j_ijid_2021_07_003 |
PublicationCentury | 2000 |
PublicationDate | August 2021 2021-08-00 20210801 2021-08-01 |
PublicationDateYYYYMMDD | 2021-08-01 |
PublicationDate_xml | – month: 08 year: 2021 text: August 2021 |
PublicationDecade | 2020 |
PublicationTitle | International journal of infectious diseases |
PublicationYear | 2021 |
Publisher | Elsevier Ltd Elsevier |
Publisher_xml | – name: Elsevier Ltd – name: Elsevier |
References | Kim, Kim, Park, Kim, Yu, Chang (bib0005) 2021; 10 Ni, Ye, Cheng, Feng, Deng, Zhao (bib0008) 2020; 52 Van Elslande, Vermeersch, Vandervoort, Wawina-Bokalanga, Vanmechelen, Wollants (bib0013) 2020 Voysey, Clemens, Madhi, Weckx, Folegatti, Aley (bib0014) 2021; 397 Hall, Foulkes, Charlett, Atti, Monk, Simmons (bib0004) 2021; 397 Percivalle, Cambiè, Cassaniti, Nepita, Maserati, Ferrari (bib0010) 2020; 25 O Murchu, Byrne, Carty, De Gascun, Keogan, O'Neill (bib0009) 2021 Tillett, Sevinsky, Hartley, Kerwin, Crawford, Gorzalski (bib0011) 2021; 21 Baden, El Sahly, Essink, Kotloff, Frey, Novak (bib0001) 2021; 384 Lumley, O'Donnell, Stoesser, Matthews, Howarth, Hatch (bib0006) 2021; 384 To, Hung, Ip, Chu, Chan, Tam (bib0012) 2020 Muecksch, Wise, Batchelor, Squires, Semple, Richardson (bib0007) 2021; 223 Grifoni, Weiskopf, Ramirez, Mateus, Dan, Moderbacher (bib0003) 2020; 181 (bib0002) 2021 Kim (10.1016/j.ijid.2021.07.003_bib0005) 2021; 10 To (10.1016/j.ijid.2021.07.003_bib0012) 2020 Ni (10.1016/j.ijid.2021.07.003_bib0008) 2020; 52 Percivalle (10.1016/j.ijid.2021.07.003_bib0010) 2020; 25 Baden (10.1016/j.ijid.2021.07.003_bib0001) 2021; 384 (10.1016/j.ijid.2021.07.003_bib0002) 2021 Muecksch (10.1016/j.ijid.2021.07.003_bib0007) 2021; 223 O Murchu (10.1016/j.ijid.2021.07.003_bib0009) 2021 Tillett (10.1016/j.ijid.2021.07.003_bib0011) 2021; 21 Grifoni (10.1016/j.ijid.2021.07.003_bib0003) 2020; 181 Van Elslande (10.1016/j.ijid.2021.07.003_bib0013) 2020 Voysey (10.1016/j.ijid.2021.07.003_bib0014) 2021; 397 Lumley (10.1016/j.ijid.2021.07.003_bib0006) 2021; 384 Hall (10.1016/j.ijid.2021.07.003_bib0004) 2021; 397 |
References_xml | – year: 2020 ident: bib0013 article-title: Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain publication-title: Clin Infect Dis contributor: fullname: Wollants – volume: 384 start-page: 403 year: 2021 end-page: 416 ident: bib0001 article-title: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine publication-title: N Engl J Med contributor: fullname: Novak – volume: 384 start-page: 533 year: 2021 end-page: 540 ident: bib0006 article-title: Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers publication-title: N Engl J Med contributor: fullname: Hatch – volume: 223 start-page: 389 year: 2021 end-page: 398 ident: bib0007 article-title: Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients publication-title: J Infect Dis contributor: fullname: Richardson – volume: 21 start-page: 52 year: 2021 end-page: 58 ident: bib0011 article-title: Genomic evidence for reinfection with SARS-CoV-2: a case study publication-title: Lancet Infect Dis contributor: fullname: Gorzalski – volume: 10 start-page: 152 year: 2021 end-page: 160 ident: bib0005 article-title: Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission publication-title: Emerg Microbes Infect contributor: fullname: Chang – start-page: e2260 year: 2021 ident: bib0009 article-title: Quantifying the risk of SARS-CoV-2 reinfection over time publication-title: Rev Med Virol contributor: fullname: O'Neill – volume: 397 start-page: 1459 year: 2021 end-page: 1469 ident: bib0004 article-title: SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative healthcare workers in England: a large, multicentre, prospective cohort study (SIREN) publication-title: Lancet contributor: fullname: Simmons – volume: 52 year: 2020 ident: bib0008 article-title: Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals publication-title: Immunity contributor: fullname: Zhao – year: 2021 ident: bib0002 article-title: Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA. April 08th, 2021 – volume: 181 year: 2020 ident: bib0003 article-title: Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals publication-title: Cell contributor: fullname: Moderbacher – volume: 25 year: 2020 ident: bib0010 article-title: Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as of April 06th, 2020 publication-title: Euro Surveill contributor: fullname: Ferrari – year: 2020 ident: bib0012 article-title: COVID-19 reinfection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole-genome sequencing publication-title: Clin Infect Dis contributor: fullname: Tam – volume: 397 start-page: 99 year: 2021 end-page: 111 ident: bib0014 article-title: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK publication-title: Lancet contributor: fullname: Aley – volume: 52 year: 2020 ident: 10.1016/j.ijid.2021.07.003_bib0008 article-title: Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals publication-title: Immunity doi: 10.1016/j.immuni.2020.04.023 contributor: fullname: Ni – volume: 397 start-page: 1459 year: 2021 ident: 10.1016/j.ijid.2021.07.003_bib0004 article-title: SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative healthcare workers in England: a large, multicentre, prospective cohort study (SIREN) publication-title: Lancet doi: 10.1016/S0140-6736(21)00675-9 contributor: fullname: Hall – year: 2020 ident: 10.1016/j.ijid.2021.07.003_bib0013 article-title: Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain publication-title: Clin Infect Dis contributor: fullname: Van Elslande – volume: 384 start-page: 403 year: 2021 ident: 10.1016/j.ijid.2021.07.003_bib0001 article-title: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa2035389 contributor: fullname: Baden – volume: 384 start-page: 533 year: 2021 ident: 10.1016/j.ijid.2021.07.003_bib0006 article-title: Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers publication-title: N Engl J Med doi: 10.1056/NEJMoa2034545 contributor: fullname: Lumley – volume: 25 year: 2020 ident: 10.1016/j.ijid.2021.07.003_bib0010 article-title: Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as of April 06th, 2020 publication-title: Euro Surveill doi: 10.2807/1560-7917.ES.2020.25.24.2001031 contributor: fullname: Percivalle – volume: 10 start-page: 152 issue: 1 year: 2021 ident: 10.1016/j.ijid.2021.07.003_bib0005 article-title: Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission publication-title: Emerg Microbes Infect doi: 10.1080/22221751.2021.1872352 contributor: fullname: Kim – volume: 181 year: 2020 ident: 10.1016/j.ijid.2021.07.003_bib0003 article-title: Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals publication-title: Cell doi: 10.1016/j.cell.2020.05.015 contributor: fullname: Grifoni – volume: 223 start-page: 389 issue: 3 year: 2021 ident: 10.1016/j.ijid.2021.07.003_bib0007 article-title: Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients publication-title: J Infect Dis doi: 10.1093/infdis/jiaa659 contributor: fullname: Muecksch – year: 2021 ident: 10.1016/j.ijid.2021.07.003_bib0002 – volume: 21 start-page: 52 year: 2021 ident: 10.1016/j.ijid.2021.07.003_bib0011 article-title: Genomic evidence for reinfection with SARS-CoV-2: a case study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(20)30764-7 contributor: fullname: Tillett – year: 2020 ident: 10.1016/j.ijid.2021.07.003_bib0012 article-title: COVID-19 reinfection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole-genome sequencing publication-title: Clin Infect Dis contributor: fullname: To – start-page: e2260 year: 2021 ident: 10.1016/j.ijid.2021.07.003_bib0009 article-title: Quantifying the risk of SARS-CoV-2 reinfection over time publication-title: Rev Med Virol contributor: fullname: O Murchu – volume: 397 start-page: 99 year: 2021 ident: 10.1016/j.ijid.2021.07.003_bib0014 article-title: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK publication-title: Lancet doi: 10.1016/S0140-6736(20)32661-1 contributor: fullname: Voysey |
SSID | ssj0004668 |
Score | 2.4287145 |
Snippet | •Immunity from natural SARS-CoV-2 infection is protective in healthcare workers•Secondary infection is associated with low or absent serum neutralizing... OBJECTIVEThe protection from SARS-CoV-2 infection induced by SARS-CoV-2 anti-S1 and anti-S2 IgG antibody positivity resulting from natural infection was... • Immunity from natural SARS-CoV-2 infection is protective in healthcare workers • Secondary infection is associated with low or absent serum neutralizing... Objective: The protection from SARS-CoV-2 infection induced by SARS-CoV-2 anti-S1 and anti-S2 IgG antibody positivity resulting from natural infection was... |
SourceID | doaj pubmedcentral proquest crossref elsevier |
SourceType | Open Website Open Access Repository Aggregation Database Publisher |
StartPage | 199 |
SubjectTerms | immune protection neutralizing antibody SARS-CoV-2 infection secondary infection |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQDxUSQlBALI9qkLghi8Sxk7i3pWpVkMqBFtSbFTuOSIUSlN097B_kd3XGTpbNpVy4RXnZyUzmEX_fDGPvZaVyV9QZlwo1WDYu4TZzBXeJFr6QOstD077Lr_nFd_nlRt3stfoiTFgsDxxf3Eed2NxjDKIoF9GZ1D6z6OIkUUqbRDbB-iZ6SqZ2jMhIgkP3xnWRipEuE5Fd7W1LNUJFGsp2Tu2yRpcUKvfPPNNe5DnHTe45ovMn7PEYQcIyzvwpe-C7I3Z4Oa6RH7FH8U8cRILRM_YHTUDsHAp9A1fLb1f8tP_BBUw4rA63IPIhgYBgQFgtjAqBqCcQFnb80MFnDNO3QF6vBrwGJdLavt4CUZI2qxNoiWniYSz8QLcN168o466rYft3PA5LGPx66CeaJ_R293MYH83hGHzE0P_C0UIJ3Ofs-vzs-vSCj90buJO6XKOZrapCaWGFbHJrawzm0Mg3rnboH5WysmispzbBovYq1y5JS6_TrCyVU3nlshfsoOs7_5KBdGhkFB6sK0z_pNVljqrn0RwJbctKLdiHSX7md6zRYSbw2q0haRuStkloqT1bsE8k4t2ZVF877ECtM6PWmX9p3YKpSUHMGKrEEARv1d47-LtJmwx-x7Q4U3W-36wMpnaUDqdSLFgxU7PZTOdHuvZnqAheUlaqslf_49Fes4c04QhyfMMO1sPGv8XAa22Pwzd2ByyVLDg priority: 102 providerName: Directory of Open Access Journals |
Title | Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study |
URI | https://dx.doi.org/10.1016/j.ijid.2021.07.003 https://search.proquest.com/docview/2550261142 https://pubmed.ncbi.nlm.nih.gov/PMC8260553 https://doaj.org/article/90b6e310521849349e3b91043935f04f |
Volume | 109 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKKyEkhEoBsTxWRuKGwuZhJzG33VWrllIk2FLtzYodB1KhpMruHvbCz-N3MWM77ebSA5do83DszYznYc83Q8h7VvBUZ2USMA4czCodBirRWaBDEZuMiSS1RfsuvqanP9jnJV_ukXmPhcGwSi_7nUy30tpfmfivObmp68kiAt0lsigGpyXkPAe__SAG6xdm58F0dnX-ZQce6RBx8HyADTx2xoV51dc1JgyNI5vDs6-d5fWTTeM_UFM7ZugwiHJHK50ckifenKRTN-KnZM80R-Thhd8wPyKP3bIcdWijZ-QvyANXRpS2FV1Mvy-CeXsVxLQPymrgF3XgSIpRYRQDt8BEpIhDoXaXx3QNPQObfUtRBZYU2gB5atWWW4r4pM3qE60RdmKozwKBr7XtV-h-l0W3vesvoFPamXXX9phP2qrblWL4axr6CHxA_W_ozebDfU4uT44v56eBL-UQaCbyNcjcosi4iFXMqlSpEiw7kPiVLjUoS84VyyplsGZwXBqeCh1GuRFRkudc87TQyQuy37SNeUko0yBxONwsC_AFmRJ5CnxoQDbFQuUFH5EPPf3kjUvYIftItmuJ1JZIbRnivnsyIjMk8e2TmGzbXmi7n9JzmxShSg2YwRzdYZEwYRIFVhZDVHMVsmpEeM8gcsC78Kr63s7f9dwkYVLjTk3RmHazkuDnoW8csXhEsgGbDUY6vNPUv2x68BxdVJ68-s9RvSaP8MwFOb4h--tuY96C4bVWY_Lg459o7KfX2C5fwPFsOYPj-bf8H_BTM-c |
link.rule.ids | 230,315,783,787,867,888,2109,3513,4509,27581,27936,27937,45597,45675,45886 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqIgESQlBALE8jcUOmedhJzG1ZUW2h2wO7oN6s2HFKKpRU2d3DXvh5_C5mbKdsLhy4RbEdO5nJPOz5Zgh5y0uRmbxKGRfAwbw2EdOpyZmJZGJzLtPMFe1bnGfzb_zzhbg4ILMBC4NhlUH2e5nupHW4cxy-5vF10xwvY9BdMo8TcFoiIQrw229xtI-Bqd__ivfAkR4PB70Zdg_IGR_k1Vw1mC40iV0Gz6FyVtBOLon_SEntGaHjEMo9nXTygNwPxiSd-vU-JAe2PSK3F-G4_Ijc85ty1GONHpHfIA18EVHa1XQ5_bpks-47S-gQktXCFfXQSIoxYRTDtsBApIhCoe6Mx_YtPQWLfUdRAVYUxgBxGt1VO4ropO36A20QdGJpyAGBj3Xj1-h8V2W_-zsfo1Pa203fDYhP2umbfWJ4NQNzsBBO_xNmc9lwH5PVyafVbM5CIQdmuCw2IHHLMhcy0QmvM60rsOtA3temMqAqhdA8r7XFisFJZUUmTRQXVsZpUQgjstKkT8hh27X2KaHcgLwR0FiV4AlyLYsMuNCCZEqkLkoxIe8G-qlrn65DDXFsVwqprZDaKsJT93RCPiKJb3piqm13o-svVeA1JSOdWTCCBTrDMuXSphpsLI6Y5jri9YSIgUHUiHPhUc0_J38zcJOCXxrPacrWdtu1Ai8PPeOYJxOSj9hstNJxS9v8cMnBC3RQRfrsP1f1mtyZrxZn6uz0_MtzchdbfLjjC3K46bf2JZhgG_3K_WJ_ABQ9McI |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Incidence+of+SARS-CoV-2+infection+in+health+care+workers+from+Northern+Italy+based+on+antibody+status%3A+immune+protection+from+secondary+infection-+A+retrospective+observational+case-controlled+study&rft.jtitle=International+journal+of+infectious+diseases&rft.au=Rovida%2C+Francesca&rft.au=Cassaniti%2C+Irene&rft.au=Percivalle%2C+Elena&rft.au=Sarasini%2C+Antonella&rft.date=2021-08-01&rft.pub=Elsevier+Ltd&rft.issn=1201-9712&rft.eissn=1878-3511&rft.volume=109&rft.spage=199&rft.epage=202&rft_id=info:doi/10.1016%2Fj.ijid.2021.07.003&rft.externalDocID=S1201971221005580 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1201-9712&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1201-9712&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1201-9712&client=summon |